Compare Davita Inc (DVA) vs Honeywell International Inc (HON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Honeywell International Inc — how do they compare? Davita Inc trades at $230.69 (market cap $14.92B), while Honeywell International Inc trades at $221.39 (market cap $70.55B). The key difference: Honeywell International Inc is far larger — about 4.7× Davita Inc's market cap, and Honeywell International Inc pays a 4.28% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | HON | |
|---|---|---|
Market Cap | $14.92B | $70.55B |
Sector | Health | Industrials |
52-Week High | $235.71 | $248.04 |
52-Week Low | $103.87 | $188.14 |
Enterprise Value | $27.47B | $94.90B |
Dividend Yield | — | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Honeywell (HON) trades at $222.25, down 1.84% on the day, with a bearish technical signal. The company reported strong recent earnings beats but faces near-term uncertainty from its Aerospace and Quantinuum spinoffs. Key financials show solid profitability with a 10.89% net margin and 26.41% ROE, though revenue declined slightly in 2025. A recent 2:1 reverse stock split and updated 2026 guidance aim to streamline operations. Analyst consensus remains strongly bullish with a $368.55 price target, but technical indicators suggest caution.
The outlook for HON hinges on successful execution post-spinoff and margin improvement targets. Investment opportunity lies in its focused automation and industrial technology portfolio, attractive valuation (P/E 17.75), and strong analyst support. Key risks include near-term earnings volatility, competitive pressures, and macroeconomic headwinds impacting industrial demand. The stock's current bearish technical trend warrants monitoring for stabilization above key support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
